August 2025
1. ILSON DH
   KEYNOTE-585 Fails While Matterhorn Succeeds in Gastric Cancer: What Lessons Can We Learn?
   J Clin Oncol. 2025 Aug 19:JCO2501439. doi: 10.1200/JCO-25-01439.
   

   >> Share

   
   
2. SHITARA K, Lorenzen S, Li J, Bai Y, et al
   Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study.
   J Clin Oncol. 2025;43:2502-2514.
   

   >> Share

   
   July 2025
3. SEWASTJANOW-SILVA M, Xiao L, Abdelhakeem A, Pabon CM, et al
   Survival Benefit of Palliative Oophorectomy for Patients With Ovarian Metastasis From Baseline Metastatic Gastric Adenocarcinoma.
   J Clin Oncol. 2025;43:2361-2371.
   

   >> Share

   
   
4. KAWAKAMI H, Kadowaki S, Makiyama A, Tsuda M, et al
   Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer.
   J Clin Oncol. 2025;43:2184-2195.
   

   >> Share

   
   May 2025
5. SAKAI D, Kadowaki S, Kawabata R, Hara H, et al
   Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial.
   J Clin Oncol. 2025 May 23:JCO2401119. doi: 10.1200/JCO.24.01119.
   

   >> Share

   
   January 2025
6. KLEMPNER SJ, Sonbol MB, Wainberg ZA, Uronis HE, et al
   DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish.
   J Clin Oncol. 2025;43:339-349.
   

   >> Share

   
   October 2024
7. LI C, Tian Y, Zheng Y, Yuan F, et al
   Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05).
   J Clin Oncol. 2024 Oct 9:JCO2400795. doi: 10.1200/JCO.24.00795.
   

   >> Share

   
   
8. PAVLAKIS N, Shitara K, Sjoquist K, Martin A, et al
   INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer.
   J Clin Oncol. 2024 Oct 4:JCO2400055. doi: 10.1200/JCO.24.00055.
   

   >> Share

   
   July 2024
9. KANG YK, Kim HD, Yook JH, Park YK, et al
   Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY.
   J Clin Oncol. 2024 Jul 12:JCO2302167. doi: 10.1200/JCO.23.02167.
   

   >> Share

   
   June 2024
10. SORSCHER S
    Helicobacter pylori and Gastric Cancer Screening.
    J Clin Oncol. 2024 Jun 27:JCO2400509. doi: 10.1200/JCO.24.00509.
    

    >> Share

    
    
11. HEGEWISCH-BECKER S, Mendez G, Chao J, Nemecek R, et al
    First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study.
    J Clin Oncol. 2024;42:2080-2093.
    

    >> Share

    
    
12. JANJIGIAN YY, Ajani JA, Moehler M, Shen L, et al
    First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.
    J Clin Oncol. 2024;42:2012-2020.
    

    >> Share

    
    
13. BUTT J, Epplein M
    Potent Tool: Helicobacter pylori Treatment to Reduce the Risk of Both Gastric and Colorectal Cancers.
    J Clin Oncol. 2024;42:1865-1867.
    

    >> Share

    
    March 2024
14. SALANI F, Vivaldi C, Rreka E, Genovesi V, et al
    Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Carcinomatosis: The Need for Clear Answers Through Proper Questions.
    J Clin Oncol. 2024 Mar 14:JCO2302611. doi: 10.1200/JCO.23.02611.
    

    >> Share

    
    February 2024
15. ZHU M, Yoon HH
    Neoadjuvant Immunotherapy in Gastroesophageal Cancer: A Promising Early Signal?
    J Clin Oncol. 2024;42:373-377.
    

    >> Share

    
    
16. GALLANIS AF, Gamble LA, Samaranayake SG, Lopez R, et al
    Costs of Cancer Prevention: Physical and Psychosocial Sequelae of Risk-Reducing Total Gastrectomy.
    J Clin Oncol. 2024;42:421-430.
    

    >> Share

    
    December 2023
17. MOEHLER M, Xiao H, Blum SI, Elimova E, et al
    Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649.
    J Clin Oncol. 2023;41:5388-5399.
    

    >> Share

    
    November 2023
18. LORENZEN S, Gotze TO, Thuss-Patience P, Biebl M, et al
    Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.
    J Clin Oncol. 2023 Nov 14:JCO2300975. doi: 10.1200/JCO.23.00975.
    

    >> Share

    
    
19. DEL RIVERO J, Perez K, Kennedy EB, Mittra ES, et al
    Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
    J Clin Oncol. 2023;41:5049-5067.
    

    >> Share

    
    October 2023
20. RAU B, Lang H, Koenigsrainer A, Gockel I, et al
    Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial.
    J Clin Oncol. 2023 Oct 31:JCO2202867. doi: 10.1200/JCO.22.02867.
    

    >> Share

    
    
21. LEE CK, Kim HS, Jung M, Kim H, et al
    Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study.
    J Clin Oncol. 2023 Oct 26:JCO2300971. doi: 10.1200/JCO.23.00971.
    

    >> Share

    
    September 2023
22. KIM CG, Jung M, Kim HS, Lee CK, et al
    Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric or Gastroesophageal Junction Cancer.
    J Clin Oncol. 2023;41:4394-4405.
    

    >> Share

    
    March 2023
23. SHAH MA, Kennedy EB, Alarcon-Rozas AE, Alcindor T, et al
    Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.
    J Clin Oncol. 2023;41:1470-1491.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share